A CaseWise™ Webcast – Precision in Practice: Individualizing FcRn Inhibitor Use in Generalized Myasthenia Gravis

Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disease that can profoundly disrupt strength and independence through unpredictable, fluctuating muscle weakness. Recent advances have transformed the treatment landscape, with targeted therapies such as neonatal Fc receptor (FcRn) inhibitors and complement inhibitors expanding options beyond traditional standards of care. Because gMG is so rare, however, many clinicians only ever encounter a handful of cases – making timely recognition and accurate diagnosis a persistent challenge. As a result, opportunities to establish an accurate diagnosis, identify appropriate treatment candidates, and optimize long-term outcomes are often missed. Even for patients whose disease is considered clinically managed, treatment burden, adverse effects, and ongoing quality-of-life challenges remain significant. Evidence-based education can empower clinicians and multidisciplinary care teams to recognize gMG sooner, confidently navigate evolving treatment strategies, and identify appropriate candidates for novel therapies to enhance the lives of individuals living with gMG.

In this CME Outfitters recorded webcast, expert faculty will use real-world cases and perspectives from across the gMG care team to strengthen candidate recognition, evidence-based treatment selection, longitudinal monitoring, and shared decision-making. Education will clarify team roles and support individualized care, addressing symptom fluctuation, safety, administration preferences, treatment burden, and outcomes most meaningful to patients, including minimal symptom expression and preserved daily function.

At the conclusion of this activity, learners will be able to better:

• Identify appropriate clinical and diagnostic features in patients with newly diagnosed or early gMG who may be appropriate candidates for FcRn-directed therapy using clinical phenotype, antibody status, and current evidence
• Individualize FcRn-targeted therapy strategies based on product-specific dosing, safety considerations, and patient-specific factors in gMG
• Select collaborative, team-based approaches to patient-centered monitoring and SDM strategies that individualize treatment plans around symptom fluctuation, route and frequency preference, safety, and goals such as minimal symptom expression

Supported through an independent educational grant from argenx.

Primary: Neurologists, neuromuscular specialists, nurse practitioners (NPs), and physician associates (PAs)
Secondary: Specialty pharmacists, infusion nurses, neuro-ophthalmologists, emergency clinicians, pulmonologists, critical care clinicians, and primary care clinicians

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Amato reports the following financial relationships:

Advisory Board: argenx

Consultant: argenx

Dr. Alusma-Hibbert reports no financial relationships to disclose.

Dr. Gable reports the following financial relationships:

Advisory Board: argenx; CSL Behring; and Grifols

Consultant: argenx; Immunovant, Inc.; and Sanofi

Dr. Hehir reports the following financial relationships:

Consultant: argenx; Dianthus Therapeutics, Inc.; Johnson & Johnson; and UCB, Inc.

Dr. Vu reports the following financial relationships:

Advisory Board: Alexion/AstraZeneca Rare Disease; argenx; Amgen Inc.; Dianthus Therapeutics, Inc.; Johnson & Johnson; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; and Vor Bio

Consultant: Alexion/AstraZeneca Rare Disease; argenx; Amgen Inc.; Dianthus Therapeutics, Inc.; Johnson & Johnson; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Takeda Pharmaceutical Company Limited; and Vor Bio

Grants: Alexion/AstraZeneca Rare Disease; Amgen Inc.; argenx; Cartesian Therapeutics, Inc.; COUR Pharmaceuticals; Dianthus Therapeutics, Inc.; EMD Serono; ImmunAbs Inc.; Immunovant, Inc.; Johnson & Johnson; NMD Pharma; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; UCB, Inc.; Vertex Pharmaceuticals Incorporated; and Vor Bio

Research Support: Alexion/AstraZeneca Rare Disease; Amgen Inc.; argenx; Cartesian Therapeutics, Inc.; COUR Pharmaceuticals; Dianthus Therapeutics, Inc.; EMD Serono; ImmunAbs Inc.; Immunovant, Inc.; Johnson & Johnson; NMD Pharma; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; UCB, Inc.; Vertex Pharmaceuticals Incorporated; and Vor Bio

Speakers Bureau: Alexion/AstraZeneca Rare Disease; Amgen; argenx; CSL Behring; and Johnson & Johnson

Tsungani Clemons-Black reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Felicia G. Oyedepo, MD (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

WCV-156-100126-91